StemCell Therapy

NEW YORK, United States Nancy Pelosi has always worn Michael Kors. She told him his clothes make her feel strong, and God knows thats something she needs in Washington. Before his show on Wednesday, Kors was talking about how its more important than ever to take a stand for your principles. If youre going to do battle, youd better feel confident doing it, he said. Thats the simple truth. If youre tugging at your dress, and youre crippled in your shoes, and you cant handle your bag Kors proudly pointed out there wasnt a stiletto heel or a skintight dress in his new collection. And we dont have a bag in the show thats not hands-free. Instead, his woman was dressed for the "real" world. We need a chic security blanket, thats the reality.

His business turns 40 next year, and he claimed hes been thinking about clothing in terms of a security blanket more or less the whole time. Kors has always been ready with a raft of references for each new collection usually a Hollywood style icon but with this major anniversary approaching, hes begun to reference his own work.

There sure is enough of it. Two decades ago, Naomi Campbell modelled a cape in a Kors show, Tina Barney later photographed writer Joan Didion wearing it. We got a phone call saying Joan wanted to buy the cape and I couldnt breathe, the designer recalled. Her writing, her sense of stylishness always knocked me out. Give me Mailbu Joan Didion and Im there. Kors owns Barneys photo. I wake up to it every day. That cape is graphic, it stands the test of time, Kaia Gerber is wearing it in the show today, 21 years later.

Remember in Citizen Kane how the sled called Rosebud was a childhood memory representing all that was simple, good and true for the business titan Charles Foster Kane as he lay dying? Not wanting to sound morbid or anything, but I wondered if the cape might be Korss Rosebud, the thread that runs through his lifes work. Hes a mad movie buff, so the idea appealed to him. He certainly gave us a show that was the cinematic apotheosis of the cape, in every possible guise: Victorian detective, highwayman, Zorro, poncho, blanket. Coats and capes combined, collars flared into capelets.

The simple, good and true bit worked because what Kors was after was a sense of the cosiness and comfort of country dressing given a bit of spit and polish for city life. Now more than ever, the simple truth is that our customers dream of being able to unplug and get out of town, but thats not the way life works out.

So Kors sold the fantasy the joy of wide-open spaces as efficiently as hes always plugged his glamorous Hollywood-spiked re-visions of Americana. The escapism, the honesty of the West is one of the things you can be proud of as an American, no matter what. There was a pony print trench, and a full-on riding look in amidst all the caped cosiness.

Classics. Longevity. Kors has been brooding on them. Funny thing is, we now have a whole new generation of customers who never thought about fashion as investment, but the sustainability conversation has woken them up. They say, I dont have to buy a dress to wear twice to post on Instagram, I can actually buy something thats beautifully made and hang onto it. Intelligently, thats what Ive always thought but now were seeing a whole new generation approaching that idea for a different reason. Thats amazing.

But, honestly, is it so amazing, when youre presented with something as effortlessly, common-sensically glamorous as a slinky grey cashmere turtleneck elongated over a fishtail skirt pav-ed with subtly gleaming graphite sequins and anchored by lug-soled boots? At what stage in the devolution of humankind is that not going to look good?

See the rest here:
Michael Kors Broods on Longevity | Fashion Show Review, Ready-to-Wear Autumn 2020 | BoF - The Business of Fashion

THE WOODLANDS, TX - Larry Deckerhoff, MIM, well-known adviser to companies and entrepreneurs in The Woodlands (Texas), announced the continuation of The Woodlands Lunch Forum with a luncheon event scheduled for Friday, 28 February 2020 at Amerigos Grille, 25250 Grogans Park Drive in The Woodlands. The Forum is scheduled to start at 11:30 AM and last one and a half hours. Mr. Deckerhoff indicated,

The theme of this Lunch Forum is Advanced Health for the New Millennium, Immunotherapy and Rejuvenation. Among our featured speakers will be Ralph Fucetola JD, President of The Woodlands own Institute for Health Research - http://www.InHeRe.org. He will be joined by two experts in rejuvenation and immunotherapies. The short presentations will leave plenty of time to connect and enjoy the extraordinary cuisine at Amerigos Grille.

The Institute, founded in 1998, focuses on leading-edge, natural and nutritional support for vigorous aging and powerful immunity. The Institute President will introduce advanced approaches to health and longevity through the featured speakers who are positioned to inform and enlighten, in cooperation with NutraSpace, Health Matching Accounts and Natural Solutions Foundation.

Interested participants are requested to RSVP to stephen.contreras1@hotmail.com the requested donation of $50.00 includes a three course gourmet lunch. Donations in excess of luncheon value are tax-deductible.

The President of the Institute concluded:

We look forward to a growing presence in The Woodlands community as our alliances with local and regional companies and researchers continue to mature. Our research interests include areas as diverse as longevity nutrition, immunotherapy and autism retrieval.

Speakers:

1. Ralph Fucetola JD President, the Institute for Health Research http://www.InHeRe.org2. Bill Hayes, NutraSpace http://www.NutraSpace.com3. Elliot Gorog, HMA - http://www.HealthMatchingAccounts.com

More here:
The Woodlands Lunch Forum to Host Longevity and Health Event February 28th at Amerigo's Grille - Woodlands Online

TEMPLE, TX Baylor Scott and White doctors and researchers are teaming up with experts from across the state to improve the lives of heart failure patients.

Doctors explained to 25 News, those diagnosed with heart failure often have additional ailments, like arthritis, which often impede with the patients ability to exercise; and without exercise heart failure patients conditions often worsen.

Researchers at Baylor Scott and White are efforting a new study, conducting trails on alternative exercise regimens for their patients, by using aquatic therapy.

"The hypothesis is that compared to land based exercise they are going to have actually more mobility both before and after exercise and improve cardiac function" explained Catherine McNeal, M.D PHD Medical Director of Cardiac Rehabilitation at Baylor Scott and White.

McNeal's cohort, Albert Hicks, M.D MPH Medical Director of Heart Failure and Transplant, Baylor Scott and White, further explaining "we know that from many trails including our H.F. Action trail that heart failure patients who do cardiac rehab actually have increased survival...in the pool they have an opportunity to really not only get their heart rate up but also to do an activity that is something that they can do for the majority of the rest of their life."

The Baylor Scott and White team is collaborating with experts in aquatics at University of Texas and bio-engineers at Texas A&M University in their research.

Funded internally by the Baylor Cardiovascular Research Center, the teams efforts have all pointed towards positive results.

Awarded a small grant from the National Institutes of Health (NIH) the team looks forward to their findings and potentially positively impacting the lives of heart patients nationally.

Read the rest here:
Local News Doctors in Temple experimenting with aquatic therapy to improve longevity of heart patients Erin - KXXV News Channel 25

Anopheles arabiensis is an opportunistic malaria vector that rests and feeds outdoors, circumventing current vector control methods. Furthermore, this vector will readily feed on animal as well as human hosts. Targeting the vector, while feeding on animals, can provide an additional intervention for the current vector control activities. Agricultural animals are regularly vaccinated with recombinant proteins for the control of multiple endo- and ecto-parasitic infestations. The use of a Subolesin-vaccine showed a mark reduction in tick reproductive fitness. The orthologous gene of Subolesin, called Akirin in insects, might provide a valuable species-specific intervention against outdoor biting An. arabiensis. However, the biological function of this nuclear protein has not yet been investigated in this mosquito. The effects on An. arabiensis lifetable parameters were evaluated after Akirin was knocked down using commercial small-interfering RNA (siRNA) and in vitro transcribed double-stranded RNA (dsRNA). The siRNA mediated interference of Akirin significantly reduced fecundity by 17%, fertility by 23% and longevity by 32% when compared to the controls in the female mosquitoes tested. Similarly, dsRNA treatment had a 25% decrease in fecundity, 29% decrease in fertility, and 48% decrease in longevity, when compared to the control treatments. Mosquitoes treated with Akirin dsRNA had a mean survival time of 15-days post-inoculation, which would impact on their ability to transmit malaria parasites. These results strongly suggest that Akirin has a pleiotropic function in An. arabiensis longevity and reproductive fitness.

Read more from the original source:
Characterising the effect of Akirin knockdown on Anopheles arabiensis (Diptera: Culicidae) reproduction and survival, using RNA-mediated interference....

KEY POINTS

Lifestyle is among the determinants of how long you may live. For those who regularly go on excessive alcohol drinking, consuming diets full of trans fats, and observe many other unhealthy practices, may not expect to live long.

Scientists and health experts have found long ago that to have a healthier and longer life, you should exercise regularly and consume a healthy and balanced diet. You should also limit your alcohol intake and quit smoking.

It is not at all surprising that observing a healthy diet can help a lot in improving longevity. With thousands of information as to what can be the best diet, however, you can easily get confused as to which one to follow.

Fortunately, recent research has shed light on what could possibly be the best diet that can help improve longevity and at the same time, help prevent cancer. live healthy life vegan diet increase longevity Photo: Rita E - Pixabay

Vegans May Have an Edge

Findings of a new study that were published in The Journal of Nutrition concluded that the secret to a long life might lie in veganism. Leading scientists and health experts agree, saying that a vegan diet helps in warding off a lot of diseases, including cancer.

Researchers revealed that based on the findings of their recently concluded study, the bodies of vegans contain the most antioxidants. According to health experts, this is primarily due to the high intake of vegetables and fruits.

It was also found out that those who follow a vegan diet have considerably lower death rates compared to meat-consumers. This new study reinforces findings of past researches that found a vegetarian diet, which consists mostly of nuts, wholegrain, legumes, fruits, and vegetables, lowers the risk of developing major ailments. It also helps you live longer.

The Vegan Research

Researchers from Loma Linda University have proven that men who follow vegan diets live an average of ten years longer compared to non-vegetarian men. Women following vegan diets, on the other hand, can add six more years of a healthy life, helping them reach an average age of 85 years.

Loma Linda University researchers also comprised the same research team that came up with the groundbreaking Adventist Health Study-1, a study that examines nutrition and life expectancy.This study was regarded as a benchmark in the nutrition world because of its comprehensiveness in terms of the number of participants and the length of time conducted.

Loma Linda researchers, for fourteen long years, tracked the diets, lifestyle, and ailments among 34,000 volunteers who do not drink or smoke. They found several habits that could add years to your life.

For one, the volunteers were consuming plant-based foods and were also consuming a handful of nuts regularly. They are also physically active and maintain a healthy weight. According to the researchers, these lifestyle habits could give you an extra two to three years of a fruitful life.

Read more from the original source:
Protect Yourself Against Cancer And Increase Life Expectancy By Eating The Best Diet - International Business Times

To some longevity acolytes, stem cells promise the secret to eternal youth. For a hefty fee, you can pay a startup to extract your own stem cells and cryogenically freeze them, in the hope that they can one day be used in a treatment to help extend your life.

Other firms let you bank stem cells from your babys umbilical cord and placenta after childbirth, if youre convinced the high cost represents an insurance policy against future illness. Or you can follow the example of Sandra Bullock and Cate Blanchett and opt for an anti-ageing cream made with stem cells derived from the severed foreskins of newborn babies in South Korea.

Stem cells are the parent cells which give rise to other cells in our bodies. Since scientists first isolated human embryonic stem cells in a lab and grew them over 20 years ago, they have been mooted as a source of great hope for regenerative medical treatments, including for age-related degenerative conditions such as Parkinsons, Alzheimers, heart disease and stroke.

But apart from a few small-scale examples, the only stem cell-based medical treatment practised in clinics uses haematopoietic stem cells found in the blood and bone marrow which only produce blood cells for transplants in blood cancer patients. These cells are taken from a patients sibling or an unrelated donor, before being infused into a patients blood, or theyre taken from a patients own blood before being reinfused. The procedure has been used to treat blood malignancies for almost half a century, and recently multiple sclerosis too. So how likely is it that the predictions about stem cells' longevity-enhancing powers will become a reality?

In September 2019, Google banned ads for unproven or experimental medical techniques such as most stem cell therapy, citing a rise in bad actors attempting to take advantage of individuals by offering untested, deceptive treatments [that can often] lead to dangerous health outcomes. The decision was welcomed by the International Society for Stem Cell Research, which emphasised that most stem cell interventions remain experimental. Selling treatments before well-regulated clinical trials have been done, the body said, [threatens public] confidence in biomedical research and undermines the development of legitimate new therapies.

Its easy to see how less scrupulous companies can exploit the allure of stem cells, which seem to occupy a place in our collective consciousness as a kind of magical elixir. High hopes for stem cell-based therapies have grown since 2006, when the Japanese biologist Shinya Yamanaka created a new technology to reprogram adult cells, such as skin cells, into a similar state to embryonic stem cells, which are pluripotent, meaning they can develop into any tissue in the body. The Nobel prize-winning breakthrough was hailed as a major step in the study of stem cells without the need for controversial embryo research, and towards the use of these human induced pluripotent stem cells to regenerate damaged or diseased organs or effectively grow new spare parts which could treat the life-limiting and life-shortening illnesses associated with ageing.

Gerontologist Aubrey de Grey, whose Strategies for Engineered Negligible Senescence (SENS) research foundation aims to eliminate ageing-related diseases, thinks the chances well soon have stem cell based therapies are high. For anything that's in clinical trials, you're talking about maybe five years before it's available to the general public, he says, citing stem cell treatments for Parkinsons disease, currently being tested in phase two clinical trials, as one of the developments he thinks is likely to come soonest.

However, given that these trials involve a relatively small number of participants and most clinical trials ultimately fail, his predictions might be overly optimistic. Often described as a maverick, De Grey believes that humans can live forever and there is a 50 per cent chance medical advances of which stem cell therapies will play an important part will make this a reality within the next 17 years. Though living forever, he says, is not the ultimate goal but a rather large side effect of medicine which will successfully prevent or repair the damage that comes with ageing.

For New Jersey-based Robert Hariri, who co-founded Human Longevity Inc, which set its sights more modestly on making 100 the new 60, stem cells derived from placentas present especially exciting opportunities. A biomedical scientist, surgeon and entrepreneur, Hariri says his current venture Celularity which is focused on engineering placental cells, including stem cells, to create drugs for cancer and other conditions is not as concerned about the actual age number, but about preserving human performance as we age and treating the degenerative diseases that rob us of our quality of life.

Many of those working in the field, however, remain cautious in their optimism. Researchers have highlighted the potential risks of giving pluripotent cells to patients, whether they are induced or embryonic, as these cells can develop cancer-causing mutations as they grow.

Davide Danovi, a scientist at Kings College Londons Centre for Stem Cells & Regenerative Medicine, says the path to stem cell-based therapy is very long and full of hurdles. The supply chain involves challenges, he says. On the one hand, allogeneic treatments those with stem cells derived from one individual and expanded into big batches to create cells to treat many individuals have the advantage of being similar to the traditional pharmaceutical business models. The product is clear, its something that comes in a vial and can be scaled up and mass produced, Danovi says. But this treatment can present a greater risk of rejection from the patient, as opposed to the more bespoke autologous option which is more expensive and time-consuming as it involves extracting a patients own stem cells before reprogramming them.

Danovi is most excited by the potential of stem cells to treat age-related macular degeneration. In 2017 Japanese scientist Masayo Takahash led a team that administered transplants of artificially grown retinal cells created from induced pluripotent stem cells taken from donors to five patients with the eye condition, which can cause blindness, and theyre reported to be doing well. The eye, he says seems to be a place where immunity plays less of a role relative to other issues, so you can host cells which come from another individual with fewer problems [of rejection]. But, with other organs such as the liver, he says there are major conceptual problems with creating enough tissue. Its like the clean meat burger - you're talking about a production that is, in many cases, not easy to reach with the current technology.

Hariri believes placentas will solve some of the production challenges crucially, theyre an abundant commodity, with the vast majority thrown out after childbirth. His interest was sparked 20 years ago when his oldest daughter was in the womb: When I saw her first ultrasound in the first trimester, the placenta had already developed into a relatively sizable organ, even though she was just a peanut-sized embryo. Id been taught that the placenta was nothing more than an interface, but [if that was the case], you would expect that it would grow at the same rate as the embryo. His curiosity piqued, he began to see the placenta not as an interface but as a biological factory, where stem cells could be expanded and differentiated to participate in the development of that foetus. That intrigued me and I started to collect placentas and just, you know, basically disassemble them.

Placentas have numerous benefits, he says they dont carry the same ethical controversy as embryonic stem cells, for one thing. Scientists working on embryonic stem cells have to destroy an early embryo, and that option yields them a dozen cells, which have to be culture-expanded in the laboratory into billions of cells. In contrast, the placenta houses, billions and hundreds of billions of cells, which can be expanded as well, but you're starting out with a dramatically larger starting material.

Increasingly, scientists in the anti-ageing sphere are focusing on an approach that seems like the opposite of planting fresh stem cells into our bodies. Experts such as Ilaria Bellantuono at Sheffield Universitys Healthy Lifespan Institute are working towards creating senolytics medication that could kill off our senescent cells, the zombie cells that accumulate in tissues as we age and cause chronic inflammation. I think stem cells are very good for specific disease, where the environment is still young, Bellantuono says, but the data in animal models tells us that senolytics are actually able to delay the onset and reduce the severity of multiple diseases at the same time for example, there is evidence for osteoarthritis, osteoporosis, cardiovascular disease, Alzheimer's, Parkinson's, and diabetes. She explains that while human trials are still in their early stages, senolytics are likely to be more cost-effective than stem cell therapy and the status quo of older patients taking multiple pills for multiple diseases, which can interact with each other. Besides, she adds, they may actually work in tandem with stem-cell based therapies in the future, with senolytics creating a more hospitable environment in tissues to allow stem cells to do their work.

And as for the so-called penis facial? Its far from the only ultra-expensive stem cell skincare making bold anti-ageing claims but youre probably better off saving your money, as you are with the experimental medical treatments on offer. Stem cells are definitely exciting but theyre not the key to eternal youth. At least, not yet.

Robert Harari will be one of the speakers at WIRED Health in London on March 25, 2020. For more details, and to book your ticket, click here

Why do modern tomatoes taste so bad?

How Tesla became the world's most overvalued car company

Marvel at the incredible real-life Iron Man

How Slack ruined work

Follow WIRED on Twitter, Instagram, Facebook and LinkedIn

Get The Email from WIRED, your no-nonsense briefing on all the biggest stories in technology, business and science. In your inbox every weekday at 12pm sharp.

by entering your email address, you agree to our privacy policy

Thank You. You have successfully subscribed to our newsletter. You will hear from us shortly.

Sorry, you have entered an invalid email. Please refresh and try again.

Go here to read the rest:
Are stem cells really the key to making humans live longer? - Wired.co.uk

Global Longevity and Anti-senescence Therapy Market 2020: Research Methodology

The global Longevity and Anti-senescence Therapy Market is expected to grow at a significant pace, reports Acquire Market Research. Its latest research report, titled [Global Longevity and Anti-senescence Therapy Market Report, History and Forecast 2020-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application], offers a unique point of view about the global market. Analysts believe that changing consumption patterns are expected to have a great influence on the overall market. For a brief overview of the global Longevity and Anti-senescence Therapy market, the research report provides an executive summary. It explains the various factors that form an important element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

Global Longevity and Anti-senescence Therapy Market: Segmentation

The chapters of segmentation allow the readers to understand the aspects of the market such as its products, available technologies, and applications of the same. These chapters are written in a manner to describe their development over the years and the course they are likely to take in the coming years. The research report also provides insightful information about the emerging trends that are likely to define the progress of these segments in the coming years.

Download Sample PDF of Longevity and Anti-senescence Therapy Market Report @https://www.acquiremarketresearch.com/sample-request/306097/

Top Key players Mentioned in the Global Longevity and Anti-senescence Therapy Market Research Report: CohBar, TA Sciences, Unity Biotechnology, AgeX TherapeuticsInc, PowerVision Inc.

Types covered in the Longevity and Anti-senescence Therapy industry are Hemolytic Drug Therapy, Gene Therapy, ImmunOther.

Applications covered in the report are Hospital, Medical Service Institution, Drug and Device Sales.

Global Longevity and Anti-senescence Therapy Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the global Longevity and Anti-senescence Therapy market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the global Longevity and Anti-senescence Therapy market.

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Global Longevity and Anti-senescence Therapy Market: Research Methodology

The research methodologies used by the analysts play an integral role in the way the publication has been collated. Analysts have used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and precise analysis of the global Longevity and Anti-senescence Therapy market, analysts have bottom-up and top-down approaches.

Global Longevity and Anti-senescence Therapy Market: Competitive Rivalry

The research report includes an analysis of the competitive landscape present in the global Longevity and Anti-senescence Therapy market. It includes an assessment of the existing and upcoming trends that players can invest in. Furthermore, it also includes an evaluation of the financial outlooks of the players and explains the nature of the competition.

Grab Your Report at an Impressive Discount(with Corporate ID)! Please click here @https://www.acquiremarketresearch.com/discount-request/306097/

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Longevity and Anti-senescence Therapy marketChapter 2: Evaluating the leading manufacturers of the global Longevity and Anti-senescence Therapy market which consists of its revenue, sales, and price of the productsChapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and salesChapter 4: Presenting global Longevity and Anti-senescence Therapy market by regions, market share and with revenue and sales for the projected periodChapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Browse the full report Description, TOC and Table of Figure @ https://www.acquiremarketresearch.com/industry-reports/longevity-and-anti-senescence-therapy-market/306097/

Customization Available

With the given market data, Researchers offer customizations according to the companys specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Longevity and Anti-senescence Therapy market, by end-use.

Detailed analysis and profiles of additional market players.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Link:
Longevity and Anti-senescence Therapy Market 2020 Specification, Growth Drivers, Industry Analysis Forecast 2026: CohBar, TA Sciences, Unity...

The Durst Organization and The Port Authority of New York and New Jersey announced a half dozen new leases at One World Trade Center.

DADA Holdings LLC has signed a five-year lease for 4,786 s/f on the 71st floor; Princeton Longevity Center signed a 10-year lease for 11,075 s/f on the 71st floor. This will be both DADA and Princeton Longevitys first offices in New York City.

Ichnos Science Inc., moving its offices to New York City from Paramus, New Jersey, signed a seven-year and five-month lease for 10,847 s/f on the 76th floor.

Pison Stream Solutions signed a three-year lease for 10,804 s/f on the 49th floor of OWTC, making the building their global headquarters.

Also signed were two expansion deals. Symphony Communications Services has signed a one-year lease for 3,510 s/f on the 45th floor, bringing their total square footage on the floor to 12,100 s/f.

Additionally, Augustus Intelligence signed a five-year lease for 6,475 s/f on the 77th floor of OWTC, doubling their footprint with a move from the 45th floor.

We are extremely pleased with the leasing activity at One World Trade Center, said Jonathan (Jody) Durst, President of The Durst Organization.

We are beginning the year by welcoming our newest tenants DADA Holdings, Ichnos, Princeton Longevity and Pison and celebrating the success of Symphony and Augustus with their office expansions at One WTC.

Princeton Longevity Center was represented by Steven Rotter, Blake Goodman and Justin Haber of JLL.

Ichnos Sciences was represented by Cushman & Wakefields Drew Braver and Mark Zaziski.

Michael Thomas and Aidan Campbell of Colliers represented Pison. Symphony Communications Services was represented by Christopher Foerch of Savills.

And Augustus was represented by Carol Engel of CS Engel and Associates. The landlord was represented by Senior Managing Director Eric Engelhardt and Managing Director Karen Kuznick of The Durst Organization and the Newmark Knight Frank team of David Falk, Jason Greenstein, Peter Shimkin, Hal Stein and Travis Wilson.

Augustus Intelligence builds artificial intelligence products and secure infrastructure services to help enterprise clients reinvent themselves.

Pison Stream Solutions is a global leader in the research and development of chemical coatings platforms for niche markets. They implement their systems across defense, aerospace, automotive, antimicrobial, renewable energy applications, and additive platforms.

Princeton Longevity Center is a next-generation medical facility combining the most advanced technology with an integrated and individually tailored Preventive Medicine program.

A fully integrated, global biotechnology company with the spirit of a start-up, Ichnos Sciences is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology, autoimmune disease and pain.

The company, with headquarters in Paramus, N.J., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and treat patients holistically.

With a patented BEAT technology platform along with pioneering teams in Switzerland and India, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will hopefully extend and improve lives, writing a new chapter in healthcare.

Symphony offers a secure team collaboration platform that transforms the way users communicate effectively and securely with a single workflow application.

Symphony was founded in October 2014 and is headquartered in Palo Alto, CA, with offices in Hong Kong, London, New York, Paris, Singapore, Sophia-Antipolis, Stockholm and Tokyo.

One World Trade Center is the tallest building in the Western Hemisphere and home to the largest community of media and tech innovators.

The 3.1 million-square-foot LEED Gold Certified skyscraper features premier office space and some of the most spectacular views in the world.

On the 64th floor, One World Commons offers 25,000 s/f of tenant amenities including a world-class business and social hub fostering workplace creativity, collaboration, and community.

Built by The Port Authority of New York and New Jersey and The Durst Organization in a unique public-private partnership, The Durst Organization is responsible for marketing, leasing, and managing the property.

(Visited 1 times, 12 visits today)

Read this article:
Durst Organization sees flurry of new business at 1 WTC - Real Estate Weekly

Trending News: Ophthalmic Condition Linked to Blindness in Diabetes May Indicate Stroke Risk

A new phase 1 trial has demonstrated that a PRIMVAC placental malaria vaccine candidate is safe, immunogenic, and induced functional antibodies in volunteers, according to Contagion Live. The study, which marked the first in-human trial of the vaccine candidate, involved a randomized, double-blind trial in 2 staggered phase taking place between April 2016 and July 2017. Antibody titers increased with each successive dose and seroconversion was observed in all women who received the vaccination.

An ophthalmic condition linked to blindness in diabetes could serve as an additional indicator of increased stroke risk, according to HCP Live. An analysis of more than 2500 patients revealed that those who had diabetic retinopathy had an increased risk of stroke compared with patients without diabetes. The study also showed that having diabetic retinopathy was associated with a 60% higher risk of stroke compared with patients with diabetes without the ophthalmic condition. The study authors feel that more aggressive treatment for patients with a risk of stroke and who have been diagnosed with diabetic retinopathy may be warranted to reduce risk.

Visit link:
Trending News: Ophthalmic Condition Linked to Blindness in Diabetes May Indicate Stroke Risk - Pharmacy Times

Ophthalmologists announced an increase of blindness in Sudan during a workshop in Khartoum on Saturday. The reason: it is impossible to reach the marginalised areas of the country to conduct cataract operations there.

Cataract is the main cause of blindness in Sudan. It most commonly affects adults as a result of ageing.

Cataract surgery involves replacing the cloudy lens inside an eye with an artificial one. Cataracts usually get slowly worse over time. Surgery to replace the cloudy lens is the only way to improve eyesight. The operation has a high success rate.

The Sudanese ophthalmologists said that there are patients who cannot cover the costs of the operations because of poverty or dont know they can be treated.

The ophthalmologists pointed out that there are no eye hospitals in several states. Most eye operations and eye treatment are concentrated in Khartoum and the state capitals.

Radio Dabangas editorial independence means that we can continue to provide factual updates about politicaldevelopments to Sudanese and international actors, educate people about how to avoid outbreaks of infectious diseases, and provide a window to the world for those in all corners of Sudan.Support Radio Dabanga for as little as 2.50, the equivalent of a cup of coffee.

The rest is here:
Blindness from cataracts on the rise in Sudan - Radio Dabanga

You are here: Home / News / The Offensiveness Of Color-Blindness In America.Like

LikeLoveHahaWowSadAngry

1

(ThyBlackMan.com) It is difficult to argue against the fact that those among us who insist that they do not see color are balanced between being well-meaning and nave. My familiarity with such types is best expressed by an unemotional reaction to their pleadings for me to join the ranks of the historically illiterate.

Despite what the color-blind brigade believes, I understand that their emotional state vacillates between moments of frustration and uncontrollable white-rage. This matter is at the forefront of my mind due to a recent Facebook posting from what appears to be a well-meaning White lady who insists that she does not see color.

As stated above, I understand that her passion flows from a desperate desire to see all of her countrymen living in harmony. However, she fails to comprehend a fact provided by a former student who posited that America will never get past Race. It is who we are. So how can we ever get past it?

Although I agreed with my students assertion that impressively echoes W.E.B. DuBois ominous warning that the color line will be the problem of the twentieth century, I realized that the source of this post vehemently disagrees with such sensibility.

Experience has taught me that the color-blind brigade wishes for a simpler time that never existed. A cursory examination of their beliefs reveals that We never were what they thought we used to be. Many of their numbers have foolishly advanced the assertion that If we stopped talking about Race it would simply go away!!!!!

I can only imagine that if my exchange with the lady who created the alluded to post were in-person and not via social media that she would scream that I dont see color!!!!! I only see human beings to my face.

Im convinced that the color-blind argument, albeit well-meaning, primarily results from what can only be termed a loose use of language. Put simply; these people do not realize what they are actually saying in their fits of rage. If provided the opportunity to meet with representatives of the color-blind brigade, I would ask them to provide a description of me. I am certain that they would avoid physical descriptors such as my status as an African-American male.

What members of the color-blind brigade fail to consider is that their steadfast denial of physical traits is not complementary to those they are seeking to aid in their color-blindness. It is extremely insulting. They are in effect saying that they must deny a portion of my being to accept me or you. If provided the opportunity, I would advise the color-blind brigade to abandon their standard phraseology in favor of the following.

I recognize your racial identity; however, I do not ascribe any negative characteristics to you because of it.

Trust me when I say that this slight verbal alteration will make a major difference to all and hopefully open a long-overdue dialogue about Race in America.

Staff Writer;Dr. James Thomas Jones III

Official website;http://www.ManhoodRaceCulture.com

One may also connect with this brother viaTwitter;DrJamestJones.

Read more:
The Offensiveness Of Color-Blindness In America. - ThyBlackMan

The review article focuses on free radicals and oxidative stress involved in ophthalmological diseases such as retinopathy, cataract, glaucoma, etc. Oxidative stress is considered as a key factor involved in the pathology of many chronic diseases including ophthalmic complication and inflammatory process. Oxidative stress and inflammation are closely related pathophysiological processes and are simultaneously found in many pathological conditions. The free radicals produced oxidize cellular components such as lipids and phospholipids leading to lipid peroxidation and trigger the onset of retinopathy. Cataract is a significant cause of visual disability and it is proposed that the high incidence is related to oxidative stress induced by continued intraocular penetration of light and consequent photochemical generation of free radical oxidants. Glaucoma is the leading cause of irreversible blindness and comprises a group of diseases characterized by progressive optic nerve degeneration. Oxidative injury and altered antioxidant defense mechanisms in glaucoma appear to play a role in the pathophysiology of glaucomatous neurodegeneration that is characterized by death of retinal ganglion cells. The UVB radiations through this way may cause a number of diseases like photo-keratitis, pterygium, damage to epithelium, edema, and corneal cell apoptosis.: ROS: reactive oxygen species; RNS: reactive nitrogen species; O: superoxide anion; HO: hydrogen peroxide;. OH: hydroxyl radicals; ONOO, ONO peroxynitrite; NO: nitric oxide; IOP: intraocular pressure; RGC: retinal ganglion cells. WHO: World Health Organization; IAPB: International Agency for the Prevention of Blindness.

See the original post here:
Biomarkers of inflammation and oxidative stress in ophthalmic disorders. - Physician's Weekly

Sounds Right, a seven-piece band, is playing a charity night at Penwortham Arts Centre "The Venue".

Sounds Right, a seven-piece function band, will entertain music lovers on Saturday, February 29th, at Penwortham Arts Centre "The Venue" in Liverpool Road from 7pm to 10pm.

The event has been organised by Penwortham Town Council in aid of Cancer Research UK and Galloway's Society for the Blind, which is based in Howick House, Penwortham.

Trumpet player Chris Andrew said: "We think it's really important because unfortunately some members of the band have been treated by cancer specialists, so we would like to give something back."

Sounds Right formed nine months ago and comprises ex-military/police officers and cruise ship musicians. Boasting both male and female vocals, the band plays a wide range of genres, including rock and roll, Latin and traditional ballroom, and incorporates the trumpet, trombone, saxophone, keyboard, bass and drums.

Chris added: "We're called Sounds Right because our music sounds right for any occasion. I don't think Penwortham has had an event like this before so it will offer something unique."

For more information, contact Chris on 07968 185922.

The rest is here:
This musical charity night raising awareness of cancer and blindness is heading to Penwortham - Lancashire Post

Researchers have identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects more than 1.5 million people in the UK alone.

The research team, made up of scientists from Cardiff University, Queen Mary University of London, the University of Manchester, and Radboud University Medical Center, Nijmegen, found significantly higher levels of a protein called factor H-related protein 4 (FHR-4) in the blood of AMD patients.

Further investigation, using eye tissue donated for medical research, showed the presence of the FHR-4 protein within the macula the specific region of the eye affected by the disease.

The results of the study, published today in Nature Communications, open up new routes for the early diagnosis, by measuring FHR-4 levels in the blood, and suggests therapies targeting this protein could provide promising future treatment options for the disease.

Professor Paul Morgan, an expert in complement biology at Cardiff University, and leader in the development of the antibodies and assays that underpinned this work, said: The collaboration between experts in complement biology, eye disease and genetics across Europe has enabled the accumulation of a robust body of evidence that genetically dictated FHR-4 levels in plasma are an important predictor of risk of developing AMD.

Read this article:
International team delivers research breakthrough for leading cause of blindness - Mirage News

An Emirati man donated Dh10.5 million to a campaign that aims to end river blindness.

Bader Al Hilali, a philanthropist, made the donation to the Reach Campaign, an Emirates Red Crescent-organised drive that targets neglected tropical diseases, which are little known in the wider world but devastating for sufferers.

"It gives me immense pride to support the Reach Campaign and join its noble goal to end river blindness. I am particularly pleased the campaign launched first in the UAE, further illustrating our culture of generosity and

humanity. I look forward to seeing our community come together to tackle this urgent issue and help improve the lives of millions around the world," Mr Al Hilali said on Wednesday.

The Reach Campaign launched two weeks ago and uses the theme Give 2, Save 2 meaning that a Dh2 donation is enough to provide the medicine and treatment to protect one person against both diseases for an entire year - to encourage donations.

More than 200 million people worldwide require treatment for river blindness, one of the leading causes of preventable blindness. It is caused by repeated bites by black flies that live near flowing water.

Like many neglected tropical diseases, river blindness disproportionately affects the worlds most vulnerable people, trapping their families in cycles of poverty. Most of the cases are found in 31 countries in sub-Saharan Africa.

Proceeds from the campaign will go to the Reaching the Last Mile Fund, which delivers prevention and treatment across seven countries in Africa and the Middle East.

All the information can be found on the Reach website and using the social media handle, @reachtheendorg.

Updated: February 13, 2020 01:56 PM

Continued here:
Emirati donates Dh10.5m to campaign to end river blindness - The National

Abstract / Synopsis:

AAV8-RPGR gene therapy for X-linked retinitis pigmentosa showed early responses to treatment at one month with increased retinal sensitivity with retinal toxicity.

This article was reviewed by Paulo E. Stanga, MD

The results of treatment of X-linked retinitis pigmentosa (XLRP) with AAV8-RPGR gene therapy proved to be early and effective with durable improvements in vision occurring as early as one month following treatment.

XLRP, a rare disease that comprises 10% to 20% of RP worldwide, affects mostly males, and 70% of the cases are caused by RPGR gene mutations and 60% of those are caused by gene mutations in RPGR-ORF15. In this form of RP, the median age of blindness is 45 years, which is younger than the other forms.

Disease progression occurs in stages, with nyctalopia manifesting in the early stage, peripheral visual field constriction in the middle stage, and central visual deterioration and visual loss in the end stage, according to Paulo E. Stanga, MD, professor of Ophthalmology and Retinal Regeneration, Manchester Royal Eye Hospital and University of Manchester, London, UK.

Related: Gene therapy offering hope for retinal, corneal patients

The RPGR mutations cause abnormal transport across the cilium, where RPGR is located, and this abnormal transport results in photoreceptor death.

Obviously, this leads to loss of retinal sensitivity across the visual field and loss of visual acuity, he said.

The treatment that Dr. Stanga and colleagues devised has the goal of correcting the full length of the RPGR-ORF15 mRNA.

We aim for yields of high expression levels that are four times higher than the expression levels of the wild-type RPGR, he explained.

Related: Research targets precision data for gene, cell therapy

Six-month Phase I resultsDr. Stanga and colleagues are currently conducting a two-year dose-escalation clinical trial. The study included men who were 18 years and older with genetically confirmed XLRP. All patients had active disease that was visible bilaterally in the maculas. The study included six cohorts, with the following levels of affect vision: 1, better than light perception; 2 and 3, 34 to 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; and 4, 5, and 6, greater than 34 ETDRS letters.

The primary endpoint was the incidence of dose-limiting toxicities and treatment-emergent adverse events. The secondary endpoints were the changes in microperimetry, visual stability, and changes in the ellipsoidal zone on spectral-domain optical coherence tomography, Dr. Stanga recounted.

The patients underwent a surgical procedure that included creation of a bleb followed by injection of the virus vector within the bleb.

Related: New vitreoretinal tools advancing surgical outcomes

The investigators evaluated the early effects of changes in the retinal sensitivity in the central retina using microperimetry (Maia, Centervue). The central 16 retinal loci represent 8 degrees of vision; an improvement of five of the central 16 loci equals a 30% improvement in the central visual field. An improvement of 7 dB represents five times greater light sensitivity, he explained.

One month after treatment, Dr. Stanga reported that there was a significant improvement in microperimetry in six of the 12 treated eyes in cohorts 3 to 6 that occurred at one month after vector injection; these cohorts received therapeutic doses. Cohorts 1 and 2, which received subtherapeutic doses, showed no changes.

Cohort 3 showed a mean improvement in the mean retinal sensitivity of 5 to 6 dB in the central 16 retinal loci between the treated and untreated eyes. The improvement became apparent at one month and remained relatively stable at three and six months, Dr. Stanga reported.

According to Dr. Stanga, these changes in retinal sensitivity differed from those observed in untreated eyes in the central 16 retinal loci. The untreated eyes showed decreases in retinal sensitivity over time.

Related: Surgeons provides pearls for handling retinal tears

The microperimetry heat maps also reflected the changes in the treated eyes with enlargement of the sensitive areas.

The investigators also reported that they also determined that the gene therapy with AAV8-RPGR gene therapy for XLRP was generally well tolerated.

No patients left the study and no dose-limiting toxicities were readily apparent.

Transient inflammation developed in the higher cohorts that responded to systemic steroid therapy. Two ocular adverse effects were related to the procedure or drug.

ConclusionsWe demonstrated proof of concept with durable dose-related improvements that appeared as early as one month after treatment across multiple microperimetry analyses, Dr. Stanga concluded. The preliminary efficacy signals were exhibited in cohorts 3 to 6, which responded to the highest doses.

Read more by Lynda Charters

Paulo E. Stanga, MDE: [emailprotected]This article is based on Dr. Stanga's presentation at the American Academy of Ophthalmology 2019 annual meeting. Dr. Stanga has no financial interest in this subject matter.

Read the original here:
Gene therapy offers treatment for X-linked retinitis pigmentosa - Modern Retina

The Emirates Red Crescent River Blindness campaign landing page Image Credit: Supplied

Dubai: Emirates Red Crescent (ERC) have launched a campaign to eradicate river blindness, a tropical disease caused by an infection from a parasitic worm, that affects more than 200 million people worldwide.

According to ERC, a donation of Dh2 can provide the medicine and treatment to protect one person from river blindness, lymphatic filariasis and several other co-endemic diseases for the entire year.

Around 21 million people worldwide are infected with river blindness while 217 million people are at risk of contracting the disease and 99 per cent of them live in Sub-Saharan Africa, according to the World Health Organisation (WHO), who have a plan in place to eradicate river blindness in select African countries by 2020.

Like many NTDs (neglected tropical diseases), river blindness disproportionately affects the worlds most vulnerable people, trapping their families in cycles of poverty. It is a threat to human development, especially in Africa. But together we can help end river blindness and ensure a brighter future for millions, said Dr. Mohammad Ateeq Al Falahi, ERC Secretary-General.

The Reach Campaign to combat river blindness in countries that suffer related health challenges reflects the growing role of the UAE and its leadership in fulfilling human and health needs, and improving lives in fragile and troubled areas, he added.

Proceeds from the campaign will go to the Reaching the Last Mile Fund (RLMF) a 10-year US$100 million (Dh367 million) initiative launched in 2017 by His Highness Shaikh Mohammad bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and several supporters.

RLMF delivers prevention and treatment across seven countries in Africa and the Middle East, including Chad, Ethiopia, Mali, Niger, Senegal, Sudan and Yemen. The fund will also be used towards the elimination of co-endemic lymphatic filariasis, which can lead to debilitating elephantiasis.

In 2018, the RLMF ahs delivered over 13.5 million treatments for river blindness and trained 76,000 health care workers to help expand treatment and outreach.

Donations can be made online via Emirates Red Crescent and via SMS, kiosks, ATM machines, and donation boxes. More information can be found via the campaign's website and across social media via @reachtheendorg.

River blindness

River blindness (also known as onchocerciasis) is caused by an infection from a parasitic worm transmitted by blackflies, which breed in fast-flowing streams and rivers. The worms produce larvae that move to the skin, eyes and other organs could lead to debilitating itching, disfiguring skin conditions and sight loss (including irreversible blindness). With these conditions, river blindness has an enormous impact on the lives of those infected by reducing their ability to work and study in school.

In numbers

21 million people worldwide are infected with river blindness217 million are at risk of contracting the disease99 per cent of them live in Sub-Saharan Africa

Read more from the original source:
Abu Dhabi-based charity seeks Dh2 donation to end river blindness - Gulf News

Stickler syndrome is the most common genetic cause of rhegmatogenous retinal detachment (RRD) in children, and has a high risk of blindness. Type I (STL1) is the most common subtype, caused by COL2A1 mutations. This study aims to analyze the mutation spectrum of COL2A1 and further elucidate the genotype-phenotype relationships in the East Asian populations with STL1, which is poorly studied at present.By searching MEDLINE, Web of Science, CNKI, Wanfang Data, HGMD and Clinvar, all publications associated with STL1 were collected. Then, they were carefully screened to obtain all reported STL1-related variants in COL2A1 and clinical features in East Asian patients with STL1.There were 274 COL2A1 variants identified in 999 patients with STL1 from 466 unrelated families, and more than half of them were truncation mutations. Of the 107 STL1 patients reported in the East Asian population, it was found that patients with truncation mutations had milder systemic phenotypes, whereas patients with splicing mutations had severer phenotypes. In addition, several recurrent variants (c.3106C>T, c.1833+1G>A, c.2710C>T and c.1693C>T) were found.Genotype-phenotype correlations should certainly be studied carefully, contributed to making personalized follow-up plans and predicting prognosis of this disorder. Genome editing holds great potential for treating inherited diseases caused by pathogenic mutations. In this study, several recurrent variants were found, providing potential candidate targets for genetic manipulation in the future.

Visit link:
Mutation Spectrum of Stickler Syndrome Type I and Genotype-phenotype Analysis in East Asian Population: a systematic review. - Physician's Weekly

In the early 2000s, it was reported that a certain kind of skin cancer treatment called photodynamic therapy, which uses light to destroy malignant cells, had a bizarre side effect: It was giving patients enhanced night time vision.

Rods and cones photoreceptors in a human retina.

Photo Credit: Dr. Robert Fariss, National Eye Institute, NIH / Flickr

"Seeing" happens when a series of receptors in the retina, the cones and rods, collect light. Rods contain a lot of rhodopsin, a photosensitive protein that absorbs visible light thanks to an active compound found in it called retinal. When retinal is exposed to visible light, it splits from rhodopsin. This then allows the light signal to be converted into an electrical signal that the visual cortex of our brains interprets into sight. Of course, there is "less light" at night, which actually means that light radiation is not in a domain visible to humans. It's at higher wavelengths (the infrared level) that retinal is not sensitive to. Hence, why we can't see in the dark like many critters can.

But the vision process can be activated by another interaction of light and chemistry. As it turns out, a chlorin e6 injection under infrared light changes retinal in the same way that visible light does. This is the cause of the unforeseen night vision side effect of the treatment.

"Molecular simulation" is a method that uses an algorithm that integrates the laws of quantum and Newtonian physics to model the functioning of a biological system over time. The team used this method to mimic the biomechanical movements of individual atoms that is, their attraction or repulsion to one another along with the making or breaking of chemical bonds.

"For our simulation we placed a virtual rhodopsin protein inserted in its lipid membrane in contact with several chlorin e6 molecules and water, or several tens of thousands of atoms," Monari explained to CNRS. "Our super-calculators ran for several months and completed millions of calculations before they were able to simulate the entire biochemical reaction triggered by infrared radiation." In nature, this phenomena occurs within fractions of a nanosecond.

The molecular simulation showed that when the chlorin e6 molecule absorbs the infrared radiation, it interacts with the oxygen present in the eye tissue and transforms it into reactive, or singlet, oxygen. In addition to killing cancer cells, "singlet oxygen" can also react with retinal to enable a slightly enhanced eyesight at night, when light waves are at the infrared level.

Now that researchers know why the "supernatural" side effect occurs, they may be able to limit the chance of it happening to patients undergoing photodynamic treatment. Thinking further out, the researchers hope for the possibility that this chemical reaction could be harnessed to help treat certain types of blindness and sensitivity to light.

Ultimately, researchers say that this has been a big flex for the power of molecular simulations, which can give us astonishing scientific insights like this.

"Molecular simulation is already being used to shed light on fundamental mechanisms for example, why certain DNA lesions are better repaired than others and enable the selection of potential therapeutic molecules by mimicking their interaction with a chosen target," Monari told CNRS.

Related Articles Around the Web

Read more here:
This cancer treatment gives patients night-vision, and we finally know why - Big Think

Here is a look at how RBIs MANI app has been designed to help the differently-abled manage their cash transactions with greater ease.

As per the National Blindness and Visually Impaired survey released by Union Health Minister Dr Harsh Vardhan in 2019, the number of people suffering from blindness has declined from 12 million in 2006-07 to 4.8 million last year. Thats certainly a welcome news.

Add to this, to aid the visually challenged in the country, in January 2020, the Reserve Bank of India (RBI) introduced a mobile app that can identify a currency notes denomination. The Mobile Aided Note Identifier, or MANI, is freely available for Android and iOS operating systems and also works offline after installation.

It is a great help for the differently abled, especially after the introduction of new notes since demonetization. These banknotes from the Mahatma Gandhi series contained features, like tactile markings and variable note sizes, to help the visually challenged. However, it still resulted in mix-ups during their daily dealings.

MANI app is designed to make it easier for the differently abled to manage their cash transactions independently. Want to know more about the app?

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Feb 12, 2020 07:40 pm

Go here to see the original:
How MANI aids differently abled to manage their cash transactions - Moneycontrol